sa-pccoc 2016 · infographic 10 consumer engagement 11 research symposium 13 consumer evening 14...
TRANSCRIPT
THE SOUTH AUSTRALIAN PROSTATE CANCER CLINICAL OUTCOMES COLLABORATIVE
SA-PCCOC
2016 A NNUA L REPORT
2 SA-PCCOC
Contents
Vision 3
Chairman’s Report 4
Research Update 6
The Registry 7
Infographic 10
Consumer Engagement 11
Research Symposium 13
Consumer Evening 14
Awards and Prizes 15
Grants Received 16
Publications 19
Committee Members 22
Collaborating Partners 27
Contact Information 28
3SA-PCCOC Vision
VisionThe South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC) is a multi-centre, multidisciplinary collaboration between men diagnosed with prostate cancer, clinicians involved in the treatment of prostate cancer and researchers.
We are committed to maintaining a comprehensive data collection of men diagnosed with prostate cancer and utilising evidence-based tools for assessing outcomes of treatment.
Aims• To undertake clinical outcomes research in order to better understand progression of prostate
cancer and ways of facilitating clinical decision-making
• To provide data to contributors relating to their clinical practice for audit and feedback purposes
• To facilitate clinical prostate cancer research for post-graduate students, surgical trainees, clinicians and researchers
• To collaborate closely with other prostate cancer registries in Australia and particularly in the Northern Territory
• To seek collaboration with other institutions and databases to validate the quality of data collection and contribute to multi-institutional research
4 Chairman’s Report SA-PCCOC
Chairman’s ReportIt is almost a truism to say, that for any organisation, each year throws up new challenges, opportunities and incremental growth. For SA-PCCOC, 2016 (our 18th year of operation) has been no exception. During this year we have captured more than 85% of all men with a new diagnosis of prostate cancer in the state and achieved “population status” of our registry.
We believe this to be not only an Australian first, but also a world first, for a non-government funded, independent cancer registry. Maintaining this figure in the future is a considerable challenge, and the fact that we have reached this status underpins the dedicated hard work of our multi-disciplinary team. We are very grateful to those men who have volunteered to be in our data base and help achieve this milestone.
Since inception it has been our aim to monitor outcomes and report on the quality of care to better understand prostate cancer in South Australia, and provide feed-back to clinicians, patients and health care workers, in order to improve and facilitate decision making. To this end we have published a total of nine papers in respected international journals, and given oral presentations and displayed posters on 25 occasions to state, national and international conferences.
The quantity of our output has been outstanding, as has the quality. One of our papers presented at the Global Congress on Prostate Cancer in Vienna won the best abstract prize. Another talk won the best presentation at the Royal Australian College of Surgeons South Australian state meeting. SA-PCCOC was a finalist for the Southern Adelaide Local Health Network Research Excellence Award.
As our data collection, output and other activities have grown, we’ve needed to expand our multi-dis-ciplinary team. This year we welcomed Dr Braden Higgs (radiation oncologist) and Sally Sara (prostate cancer specialist nurse) to the steering committee, and Dr Penny Cohen (uro-pathologist), Dr Andrew Vincent (bio-statistician), and Associate Professor Dr Nick Brook (urologist) to the research committee.
It is both sad and exciting to announce Dr Kerri Beckmann, deputy chair of the research committee, has been awarded a prestigious four year NHMRC Early Career Fellowship.
Sad, as Kerri will spend the first two years, starting 2017, at King’s College London. Fortunately she will continue to contribute to SA-PCCOC whilst overseas.
We have continued our close association with Movember, by continuing to contribute to the Prostate Cancer Outcomes Registry, Australia and New Zealand (PCOR–ANZ). We have also continued to provide our data to the Movember Foundation’s Prostate Cancer Health Outcomes Research Unit (PCHORU), which is an initiative involving Monash University, University of South Australia, and the South Australian Health and Medical Research Institutes (SAHMRI) initiative.
I would finally like to gratefully acknowledge our sponsors, particularly from the medical and pharmaceutical industries, without whose ongoing support we are unable to do the work which we believe is so important.
5SA-PCCOC Chairman’s Report
As the longest running prostate cancer registry in Australia and the southern hemisphere, SA-PCCOC’s future is bright. We have one of the largest and richest data sets of any prostate cancer organization, which includes extensive patient reported outcome measures (PROMS).
It has been a great privilege for me to continue to lead the data base and to work with colleagues who exhibit such dedication and passion to our organisation and “the cause” which is improving prostate cancer care.
Yours sincerely,
Chairman and Principal [email protected]
6 Research Update SA-PCCOC
Research UpdateThe research sub-committee of SA-PCOC has met on a regular basis through 2016 and is comprised of committee members representing various specialties including Urology, Radiation Oncology, Data Collection and Management, Statistics, Epidemiology, Uropathology and Medical Oncology. The committee continues to receive potential research ideas which are reviewed at the committee meeting for approval, amendment or rejection. The meeting also regularly reviews research projects, related directly to SA-PCCOC and commonly includes more that 30 research projects in various states of development. A number of these projects routinely proceed to publication and presentation at various meetings of repute. The committee continues to grow in both number, interests and research and this reflects the commitment of the members of the committee and collaborators as well as the robust nature of the database which continues to be reviewed and updated in line with the needs of the profession and consumers.
Thanking you
Martin BorgChair, Research committee
7SA-PCCOC The Registry
The Registry
Data collectedSA-PCCOC collects data relating to men’s prostate cancer diagnosis, treatment, pathology and surgical outcomes. Patients are also asked about the outcomes they experience such as incontinence and impotence. As at December 2016, the total number of patients recruited reached 11832 (Figure 1.). Overall, the average age of men at the time of their diagnosis was 68 years (Figure 2.). The database continues to recruit men receiving a spectrum of treatment options (Figure 3.) providing a valuable cohort for tracking the outcomes of each type of treatment over time. As the database continues to grow, it remains a challenge to maintain clinical follow-up.
Figure 1. SA-PCCOC database–growth 2007-2016
3000400050006000700080009000
10000110001200013000
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Database Growth
8 The Registry SA-PCCOC
Figure 2. SA-PCCOC database – patient age at diagnosis
Figure 3. SA-PCCOC database – patient treatment choices
0
50
100
150
200
250
300
350
400
450
500
34 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97
Age at Diagnosis
050
100150200250300350400450500
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Distribution of Treatment Choices
HORMONES RP XRT
9SA-PCCOC The Registry
2016 RecruitmentDuring 2016, 1229 patients were added to the SA-PCCOC database (Figure 4.). This represents 85% ascertainment of all prostate cancer cases diagnosed within South Australia, using data projections from the South Australia Cancer register as a denominator (Table 1.).
Of patients recruited in 2016, 33% were from public hospitals with the remaining 67% from private practices. Average age at the time of diagnosis was 68 years with most treatments being with radical prostatectomy (65%) or radiation therapy (17%).
0
200
400
600
800
1000
1200
1400
2011 2012 2013 2014 2015 2016
Annual Recruits
Michael O’CallaghanExecutive Officer
10 Infographic SA-PCCOC
InfographicSA-PCCCOC SNAPSHOT
2016Men recruited
Public –Private
Total Registry Size (at 30/12/2016)
Population coverage
Men returning questionnaires
1229
11832
85%
75%
75% 58%
9
2535
Treatment choicesRadiation Therapy 17%Surgery 65%Observation 6%Hormones 11%
Public 33%
Private 67%
Participating urologists
Active research projects
Sent to them before treatment commenced
Sent to them 5 years after treatment
Publications in 2016
Abstracts in 2016
11SA-PCCOC Consumer Engagement
Consumer EngagementSouth Australians diagnosed and treated for prostate cancer since 1998 are most certainly eligible to be included on the SA-PCCOC database. It is estimated that over 12,000 patient entries are included with an amazing record of detail for each entry.
The database, unique in the world and the longest running in Australia contains pathological and clinical details of diagnosis, treatments and patient reported outcomes for up to five years post treatment.
The collaborative believes in creating research findings which change clinical practice in the detection, the diagnosis and the treatment of prostate health issues for South Australian males.
A strategic plan was devised in 2016 to carry activities to 2021. The principal activity strands of the plan to ensure activity and growth are:
1. Our database
2. Our research
3. Our engagement with patients
4. Our finances
All of these four strategic strands are interwoven. By identifying clear recommendations for each component, the next five years can build upon the success which SA-PCCOC has earned since its inception.
The database forms the foundation of our commitment to creating research findings which change clinical practice in the detection, diagnosis and treatment of prostate cancer health issues for South Australian males. This valuable record has provided research material for over 70 scientific publications and presentations in the past three years and currently seeks to further expand this output. In October 2016 33 research projects were underway.
Those of us touched by prostate cancer need to be especially proud of this achievement, aware of findings and prepared to educate others unfamiliar with this achievement. We require especial awareness of the role of the hard working team maintaining the database.
The consumer forum “Living Well after Prostate Cancer Treatment” presented by SA-PCCOC in November 2016 received a good response from the near 200 present. It was an open meeting with opportunities for questions, a varied and informative program and was an ideal opportunity for PCFA Support Group members to extend their knowledge. There is an intention of presenting another forum in 2018.
If you participate in the data collection program, be careful and conscientious in your recording as the collection staff apply a large effort for accuracy in recording as so much research depends on this.
We have a valuable and high engagement rate with individuals and their families experiencing prostate issues. By improving this engagement with individuals, their families, clinicians and the wider
12 Consumer Engagement SA-PCCOC
community, we can increase community awareness of the issue and improve the positive impact we have already achieved. Let us all accept this challenge for a much improved outcome for affected males in South Australia.
David MerryConsumer representative
13SA-PCCOC Research Symposium
Research SymposiumIn August 2016 SA-PCCOC hosted a successful Research Symposium which brought together clinicians, researchers and patients affected by prostate cancer from around the state. The event attracted over 120 registrants and was sponsored by Tolmar Australia.
Laurate Professor Nick Talley, Editor in Chief of the Medical Journal of Australia opened the event and speakers included: Professor Wayne Tilley (University Adelaide), Phoung Tran (Adelaide Radiotherapy Centre), Professor Ian Olver (Uni SA), Chris Hocking (Adelaide Cancer Centre), Kerri Beckmann (UniSA), Professor Doug Brooks (UniSA), Ganessan Kichenadasse (FCIC), Prab Takhar (SAHMRI).
The day’s events covered topics ranging from population health strategies, new imaging and radiation treatments to cell and molecular biology. The event highlights the good will and ability of researchers and clinicians with a common interest in prostate cancer to come together, exchange ideas, and collaborate.
Photos at:
https://www.flickr.com/photos/146289425@N04/with/29115747726/
14 Consumer Evening SA-PCCOC
Consumer EveningIn November 2016, SA-PCCOC hosted a consumer forum attracting over 200 registrants.
Associate Professor Caroline Miller presented highlights from the latest prostate cancer research in SA and a well-known South Australian – Les Burdett – shared his personal experiences as a prostate cancer consumer. The second part of the evening included a panel event with health professionals from a range of backgrounds providing advice on a series of scenarios which are commonly experienced by men with prostate cancer – urinary incontinence, erectile dysfunction, employment after treatment and medication side effect to name a few. Attendees were given the opportunity to visit displays by service provides in SA including the Continence Foundation, Prostate Cancer Foundation of Australia, Cancer Council and the Freemason’s Foundation Centre for Men’s Health.
The event was sponsored by Movember and the Adelaide Radiotherapy Centre.
Photos at:
https://goo.gl/photos/J7uXLBaQoNsJmrTo9
15SA-PCCOC Awards and Prizes
Awards and Prizes
Finalists–SALHN Research Excellence Award 2016
SA-PCOCC operations team
RACS Justin Miller Medal for Clinical Research 2016 and St Pauls Ball 2016
Sophie Plagakis
Best abstract–Global Congress on Prostate Cancer – Vienna 2016
Kerri Beckmann
16 Grants Received SA-PCCOC
Grants Received
SA & NT Section of the Urological Society of Australia and New ZealandTitle: SA-PCCOC Database Sponsorship
Period of Funding: 2014-2016
Movember FoundationTitle: The Australian Prostate Cancer Clinical Cancer Registry
Investigators: Moretti KL, Pinnock C, Walsh S, Kopsaftis T, O’Callaghan ME
Period of Funding: 2014-2016
South Australian Health and Medical Research InstituteTitle: Beat Cancer Project – Data Manager Funding
Investigators: Moretti KL
Period of Funding: 2016
17SA-PCCOC Grants Received
SAHMRI and Australian Prostate Cancer
Title: Beat Cancer Project – Website Resource Funding
Investigators: Moretti KL
Period of Funding: 2016-2017
Australian Prostate Cancer
Title: Infrastructure Grant
Period of Funding: 2016
18 Grants Received SA-PCCOC
Tolmar Australia
Title: SA-PCCOC Database Sponsorship
Period of Funding: 2014-2016
Ferring Pharmaceuticals
Title: SA-PCCOC Database Sponsorship
Period of Funding: 2016-18
IpsenTitle: SA-PCCOC Database Sponsorship
Period of Funding: 2016
Adelaide Radiotherapy CentreTitle: SA-PCCOC Database Sponsorship
Period of Funding: 2016
Patient DonationsWe gratefully acknowledge patient donations received during 2016 which contribute enormously to helping advance the important research of SA-PCCOC.
19SA-PCCOC Publications
Publications
2016 Journal articles1. Prostate cancer outcomes for men who present with symptoms at diagnosis. Beckmann KR,
O’Callaghan ME, Ruseckaite R, Kinnear N, Miller C, Evans S, Roder DM, Moretti K; South Australian Prostate Cancer Clinical Outcomes Collaborative. BJU Int. 2016 Aug 4. doi: 10.1111/bju.13622. [Epub ahead of print] PMID: 27489140
2. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. Ruseckaite R, Beckmann K, O’Callaghan M, Roder D, Moretti K, Millar J, Evans S. BMC Cancer. 2016 Aug 5;16:607. doi: 10.1186/s12885-016-2655-9. PMID: 27496055
3. Prostate Cancer Registries: Current Status and Future Directions. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. Eur Urol. 2016 Jun; 69(6):998-1012. doi: 10.1016/j.eururo.2015.05.046. PMID: 26056070
4. Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013-4. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. Eur Urol. 2016 Jun;69(6):1015. doi: 10.1016/j.eururo.2015.09.036. PMID: 26443428
5. Prostate cancer in men aged less than 50 years at diagnosis. Kinnear NJ, Kichenadasse G, Plagakis S, O’Callaghan ME, Kopsaftis T, Walsh S, Foreman D. World J Urol. 2016 Nov;34(11):1533-1539. PMID: 27072535
6. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL. Ang M, Rajcic B, Foreman D, Moretti K, O’Callaghan ME. BJU Int. 2016 Apr;117 Suppl 4:68-75. doi: 0.1111/bju.13411. PMID: 26890320
7. Development of indicators to assess quality of care for prostate cancer. N Nag, J Millar, ID Davis, S Costello, JB Duthie, S Mark, W Delprado, D Smith, D Pryor, D Galvin, F Sullivan, ÁC Murphy, D Roder, H Elsaleh, D Currow, C White, M Skala, KL Moretti, T Walker, P De Ieso, A Brooks, P Heathcote, M Frydenberg, J Thavaseelan, S M Evans. European Urology Focus. http://dx.doi.org/10.1016/j.euf.2016.01.016
8. Development of an International Prostate Cancer Outcomes Registry. Evans SM, Nag N, Roder D, Brooks A, Millar JL, Moretti KL, Pryor D, Skala M, McNeil JJ. BJU Int. 2016 Apr;117 Suppl 4:60-7. doi: 10.1111/bju.13258. PMID: 26877056
9. Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset. Ruseckaite R, Beckmann K, O’Callaghan M, Roder D, Moretti K, Zalcberg J, Millar J, Evans S. BMC Res Notes. 2016 Jan 22;9:37. doi: 10.1186/s13104-016-1855-3. PMID: 26801762
20 Publications SA-PCCOC
2016 Presentation Abstracts1. Bladder neck displacement and continence outcomes within 12 months of robot assisted radical
prostatectomy. P Neumann, M O’Callaghan, D Foreman, S Plagakis, P Sutherland et al. Australian & New Zealand Continence Journal 22 (4) 2016
2. Does BMI affect continence post robotically assisted radical prostatectomy? D Lin, M O’Callaghan, D Foreman Australian & New Zealand Continence Journal 22 (4) 2016
3. Oncological outcomes in an Australian cohort according to the new International Society of Urological Pathology (ISUP-2014) prostate cancer grading categories K Beckmann, A Vincent, M O’Callaghan, F Sampurno, R Ruseckaite,et al BJU INTERNATIONAL 118, 16-17 2016
4. Age does not affect continence outcome following robot assisted laparoscopic radical prostatectomy (RALP) S Plagakis, M O’Callaghan, P Neumann, A Fuller, R Wells, P Sutherland, et al BJU INTERNATIONAL 118, 20-20 2016
5. A Cohort Study of de Novo metastatic Prostate Cancer From The South Australian Prostate Cancer Clinical Outcome Collaborative J Chan, G Kichenadasse, M O’Callagan, S Walsh, T Kopsaftis, M Borg, et al Asia-pacific Journal of Clinical Oncology 12, 34 2016
6. Application of International Society of Urological Pathology’s (ISUP) new grade categories for prostate cancer: outcomes and upgrading in South Australia (SA) K Beckmann, M O’Callaghan, A Vincent, R Ruseckaite, D Roder, S Evans, et al Urological Society of Australia and New Zealand 117, 35-36 2016
7. Prostate cancer outcomes amongst men who present with symptoms. K Beckmann, K Kinnear, M O’Callaghan, T Kopsaftis, S Walsh, D Roder, et al Urological Society of Australia and New Zealand 117, 46-47 2016
8. Validating post radiotherapy prostate specific antigen velocity for the early identification of potentially lethal prostate cancer and comparison with existing measures of treatment response. S Kinsey-Trotman, Z Shi, K Moretti, M Borg, M O’Callaghan, C Pinnock, et al Urological Society of Australia and New Zealand 117, 47 2016
9. Treatment characteristics of men with prostate cancer in Victoria and South Australia R Ruseckaite, K Beckmann, M O’Callaghan, D Roder, K Moretti, et al Urological Society of Australia and New Zealand 117, 52 2016
10. Is time to biochemical recurrence associated with mortality outcomes in prostate cancer? N Kinnear, D Foreman, G Kichenadasse, S Plagakis, M O’Callaghan, et al Urological Society of Australia and New Zealand 117, 93 2016
11. A review of the incidence, management and prognosis of the ductal subtype of prostate cancer. N Mathur, K Beckmann, M K., T Kopsaftis, K D’Onise, S Walsh, et al Urological Society of Australia and New Zealand 117, 97-98 2016
12. Clinical outcomes for rural patients with prostate cancer in South Australia. A Shepherd, K Beckmann, M O’Callaghan Urological Society of Australia and New Zealand 117, 106-107 2016
13. Radical prostatectomy vs external beam radiotherapy for high risk prostate cancer: an observational study of mortality outcomes. H Cruickshanks-Boyd, C Logan, J Johnston, J Lee, O Callaghan ME.,et al Urological Society of Australia and New Zealand 117, 82-83 2016
21SA-PCCOC Publications
14. Does the prostate imaging reporting and data system (PIRADS) version 2 (v2) improve accuracy for anterior lesions on multi parametric Magnetic Resonance Imaging (mpMRI)? C Logan, ME O’Callaghan, K Chan, K Gormly, D Foreman Urological Society of Australia and New Zealand 117, 95 2016
15. Validation of CAPRA-S in an Australian Multi-institutional Cohort. K Beckmann, M O’Callaghan, D Roder, K Moretti. The 6th Congress of Asian Pacific Prostate Society 2016, Seoul Korea, 2016
16. Oncological outcomes in an Australian cohort according to the new prostate cancer grade groups. K Beckmann, A Vincent, M O’Callaghan, F Sampurno, R Ruseckaite, et al The 6th Congress of Asian Pacific Prostate Society 2016, Seoul Korea, 2016
17. Does Body Mass Index (BMI) affect continence post radical prostatectomy? D Lin, M O’Callaghan, D Foreman. Continence Foundation of Australia’s 25th National Conference 2016
18. Oncological & functional outcome after radical prostatectomy in men presenting with locally advanced prostate cancer: South Australian experience. K Das, F Ordones, A Fuller, M O’Callaghan, NR Brooks. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
19. Does BMI affect continence post RALP? D Lin, M O’Callaghan, D Foreman. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
20. Age is not associated with continence outcomes after a robot assisted laparoscopic radical prostatectomy (RALP). S Plagakis, M O’Callaghan, P Neumann, A Fuller, R Wells, P Sutherland, et al SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
21. Localised very high risk prostate cancer. R Hoffmann, A Kahokehr, M O’Callaghan, D Foreman. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
22. Is transperineal biopsy a risk factor for positive margins and negative outcomes in patients who undergo robotic assisted radical prostatectomy? K Das, F Ordones, A Fuller, M O’Callaghan, NR Brooks. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
23. Patient reported urinary and sexual outcomes following radical prostatectomy: patterns and predictors among SA-PCCOC participants. K Beckmann, M O’Callaghan, D Roder, K Horsell, K Moretti. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
24. Survival outcomes in men with a positive family history of prostate cancer. M Ang, M O’Callaghan, M Borg. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
25. ISUP Group 4 – a Homogenous Entity? T Lu, K Moretti, M O’Callaghan. SA-NT Urological Society of Australia and New Zealand Section Meeting 2016
22 Committee Members SA-PCCOC
Committee Members
Steering Committee• Kim Moretti: Chairman & Principal Investigator
• Kym Horsell: Deputy Chairman & Treasurer
• Michael O’Callaghan: Executive Officer
• Martin Borg
• Kerri Beckmann
• Braden Higgs
• Ganessan Kichenadasse
• Tina Kopsaftis
• Scott Walsh
• David Merry
• Sally Sara
23SA-PCCOC Committee Members
Clinical Contributors• John Bolt
• Nick Brook
• Michael Chong
• David Elder
• Darren Foreman
• Andrew Fuller
• Kym Horsell
• Jimmy Lam
• Jason Lee
• John Miller
• Kim Moretti
• Kim Pese
• Adrian Porter
• Raj Singh-Rai
• Alan Stapleton
• Denby Steele
• Peter Sutherland
• Richard Wells
24 Committee Members SA-PCCOC
Research Committee• Martin Borg: Chairman
• Kerri Beckmann: Deputy chair
• Tina Kopsaftis
• Ganessan Kichenadasse
• Penny Cohen
• Scott Walsh
• Michael O’Callaghan
• Kim Moretti
• Sally Sara
• Nick Brook (commencing 2017)
• Andrew Vincent (commencing 2017)
Data Management Team• Michael O’Callaghan
• Scott Walsh
• Tina Kopsaftis
• Karen Hall
• Elspeth Raymond
• Helen Claridge
• Cathy Miller
25SA-PCCOC Committee Members
Collaborating Researchers• Darren Foreman
• Kym Horsell
• David Roder
• Sina Vatandoust
• Ned Kinnear
• Andrew Shepherd
• Nick Brook
• Branimir Rajcic
• Jonathan Cho
• Sophie Plagakis
• Patricia Neumann
• Jared Campbell
• Sue Evans
• Jeremy Millar
• John McNeil
• John Zalcberg
• Katina D’Onise
• Richard Hoffmann
• Arman Kahokehr
• Mann Ang
• Tom Lu
• Lisa Butler
• Adel Aref
• Danny Sung
• Namit Mathur
• Michelle Forgione
26 Committee Members SA-PCCOC
• Krishanu Das
• Flavio Orones
• Andrew Fuller
• Peter Sutherland
• Cruickshanks-Boyd
• Caroline Miller
• Kerry Ettridge
27SA-PCCOC Collaborating Partners
Collaborating Partners
28 Contact Information SA-PCCOC
Contact InformationSA-PCCOC: South Australian Prostate Cancer Clinical Outcomes Collaborative
Urology UnitRepatriation General Hospital
Daws RoadDaw Park
Tel +61 8 8275 1169Fax +61 8 8275 1133
Email [email protected] www.sa-pccoc.com
Signed May 2017
Professor Kim Moretti Chairman and Principal Investigator MBBS FRACS (Urol)
Dr. Michael O’Callaghan Executive Officer BSc (Hons) PhD